Table 3.
Correlation of biomarkers with response to panobinostat
| Variable | Cases with mutations | Responders with mutations | Likelihood ratio for response | Hazard ratio for progression |
|---|---|---|---|---|
| GCB | 23/35 | 5/23 | 0.65 (0.21-1.99) | 1.50 (0.67-3.35) |
| Non-GCB | 12/35 | 4/12 | — | |
| TLy* | 13/40 | 4/13 | 1.19 (0.42-3.34) | 1.43 (0.70-2.95) |
| MYC+BCL2+ | 6/27 | 0/6 | — | 3.19 (1.11-9.14) |
| CREBBP | 12/39 | 1/12 | 0.25 (0.04-1.76) | 1.58 (0.75-3.34) |
| EZH2 | 8/39 | 3/8 | 1.66 (0.55-5.02) | 0.96 (0.41 - 2.27) |
| EP300 | 1/39 | 1/1 | — | 0.49 (0.06-3.68) |
| MLL2 | 15/39 | 3/21 | 0.69 (0.21-2.25) | 1.63 (0.80 - 3.35) |
| MLL3 | 8/31 | 2/8 | 1.15 (0.28-4.80) | 1.28 (0.53-3.11) |
| MEF2B | 6/39 | 4/6 | 3.67 (1.46-9.19) | 0.58 (0.22- 1.54) |
| Any HME mutation | 25/39 | 7/26 | 1.31 (0.4-4.27) | 1.28 (0.61-2.70) |
| STAT6 | 8/39 | 3/8 | 1.66 (0.55 - 5.02) | 0.71 (0.30- 1.67) |
| FAS | 6/39 | 2/6 | 0.61 (0.09-3.98) | 1.818 (0.67-5.00) |
| CD79A/B† | 4/34 | 0/4 | — | 8.1 (1.94-33.62) |
| TP53 | 16/39 | 6/16 | 0.96 (0.32 – 2.86) | 0.83 (0.41 - 1.69) |
| PIM1 | 3/34 | 0/3 | — | 4.37 (1.02-18.70) |
| MYD88 | 6/36 | 1/6 | 0.56 (0.09-3.61) | 1.26 (0.47-3.41) |
| FOXO1 | 5/33 | 1/3 | 0.70 (0.11-4.44) | 1.38 (0.46-4.12) |
Bold values are statistically significant. Dash signifies values that could not be estimated.
COO, cell of origin; HME, histone-modifying enzyme; TLy, transformed lymphoma.
*
Of the patients with TLy, the COO was GCB in 11 and non-GCB in 2.
†
All patients with CD79A/B mutation also had dual expression of MYC and BCL2.